These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
255 related items for PubMed ID: 17559541
1. c-FLIP expression in colorectal carcinomas: association with Fas/FasL expression and prognostic implications. Korkolopoulou P, Saetta AA, Levidou G, Gigelou F, Lazaris A, Thymara I, Scliri M, Bousboukea K, Michalopoulos NV, Apostolikas N, Konstantinidou A, Tzivras M, Patsouris E. Histopathology; 2007 Aug; 51(2):150-6. PubMed ID: 17559541 [Abstract] [Full Text] [Related]
2. c-FLIP expression in bladder urothelial carcinomas: its role in resistance to Fas-mediated apoptosis and clinicopathologic correlations. Korkolopoulou P, Goudopoulou A, Voutsinas G, Thomas-Tsagli E, Kapralos P, Patsouris E, Saetta AA. Urology; 2004 Jun; 63(6):1198-204. PubMed ID: 15183989 [Abstract] [Full Text] [Related]
3. The extrinsic apoptosis pathway and its prognostic impact in ovarian cancer. Duiker EW, van der Zee AG, de Graeff P, Boersma-van Ek W, Hollema H, de Bock GH, de Jong S, de Vries EG. Gynecol Oncol; 2010 Mar; 116(3):549-55. PubMed ID: 19959214 [Abstract] [Full Text] [Related]
4. Expression level of c-FLIP versus Fas determines susceptibility to Fas ligand-induced cell death in murine thymoma EL-4 cells. Kataoka T, Ito M, Budd RC, Tschopp J, Nagai K. Exp Cell Res; 2002 Feb 15; 273(2):256-64. PubMed ID: 11822881 [Abstract] [Full Text] [Related]
9. Frequent loss of Fas expression and function in human lung tumours with overexpression of FasL in small cell lung carcinoma. Viard-Leveugle I, Veyrenc S, French LE, Brambilla C, Brambilla E. J Pathol; 2003 Oct 15; 201(2):268-77. PubMed ID: 14517844 [Abstract] [Full Text] [Related]
11. Apoptosis, proliferation, and Fas (APO-1, CD95)/Fas ligand expression in medullary carcinoma of the breast. Yakirevich E, Maroun L, Cohen O, Izhak OB, Rennert G, Resnick MB. J Pathol; 2000 Oct 15; 192(2):166-73. PubMed ID: 11004692 [Abstract] [Full Text] [Related]
12. Immunohistochemical analysis of Fas and FLIP in prostate cancers. Kim SY, Song SY, Kim MS, Lee JY, Lee HM, Choi HY, Yoo NJ, Lee SH. APMIS; 2009 Jan 15; 117(1):28-33. PubMed ID: 19161534 [Abstract] [Full Text] [Related]
15. Fas ligand and tumour counter-attack in colorectal cancer stratified according to microsatellite instability status. Michael-Robinson JM, Pandeya N, Cummings MC, Walsh MD, Young JP, Leggett BA, Purdie DM, Jass JR, Radford-Smith GL. J Pathol; 2003 Sep 15; 201(1):46-54. PubMed ID: 12950016 [Abstract] [Full Text] [Related]
16. Matrix metalloproteinase-7 increases resistance to Fas-mediated apoptosis and is a poor prognostic factor of patients with colorectal carcinoma. Wang WS, Chen PM, Wang HS, Liang WY, Su Y. Carcinogenesis; 2006 May 15; 27(5):1113-20. PubMed ID: 16474169 [Abstract] [Full Text] [Related]
19. Intracellular and extracellular remodeling effectively prevents human CD8(+)cytotoxic T lymphocyte-mediated xenocytotoxicity by coexpression of membrane-bound human FasL and pig c-FLIP(L) in pig endothelial cells. Tanemura M, Saga A, Kawamoto K, Machida T, Deguchi T, Nishida T, Sawa Y, Doki Y, Mori M, Ito T. Transplant Proc; 2009 May 15; 41(1):391-4. PubMed ID: 19249564 [Abstract] [Full Text] [Related]